|
|
|
| Analysis of CYP2C19 gene polymorphism in patients with upper digestive system diseases in Anhui Province |
| WU Lili, ZHANG Sumei, SHAO Xuanxuan, ZHANG Baozhi, ZHAO Yinsheng
|
| Department of Clincal Laboratory, The 901st Hospital of Combined Service Force of People＇s Liberation Army, Hefei, Anhui 230001, China |
|
|
|
|
Abstract Objective To analyze the CYP2C19 gene polymorphism in patients with upper digestive system diseases in Anhui Province, so as to provide evidence for individual treatment. Methods The 307 patients with upper digestive system diseases in the Department of Gastroenterology, The 901st Hospital of Combined Service Force of People＇s Liberation Army were selected. The CYP2C19 genotypes were detected by DNA microarray microarray. The CYP2C19 genotypes and metabolic types in different genders, ages and diseases were analyzed. Results There were 197 males ( 64.17% ) and 110 females ( 35.83% ) , with the age of ( 58.00±16.13 ) years old. The gene frequency of CYP2C19*1, CYP2C19*2 and CYP2C19*3 was 62.70%, 32.25% and 5.05%, respectively. There were 119 cases (38.76%) of *1/*1 ( 636GG, 681GG ), 129 cases ( 42.02% ) of *1/*2 ( 636GG, 681GA ) , 18 cases (5.86%) of *1/*3 ( 636GA, 681GG ) , 29 cases ( 9.45% ) of *2/*2 ( 636GG, 681AA ) , 11 cases ( 3.58% ) of *2/*3 ( 636GA, 681GA ) , and 1 cases ( 0.33% ) of *3/*3 ( 636AA, 681GG ). In terms of metabolisms, there were 119 cases ( 38.76% ) of fast metabolism type, 147 cases (47.88%) of intermediate metabolism type and 41 cases (13.35%) of slow metabolism type. There were no significant differences in CYP2C19 genotypes and metabolic types among the patients with different gender, age and digestive system diseases ( P＞0.05 ).Conclusion The CYP2C19 genotypes of patients with upper digestive system diseases were polymorphic, mainly the fast metabolism type and the intermediate metabolism type, which could provide reference for the clinical medication of individualized treatment of proton pump inhibitors.
|
|
Received: 14 July 2020
Revised: 24 September 2020
Published: 14 January 2021
|
|
|
|
|
|
[1] 彭净,刘卫.CYP2C19基因多态性对药物代谢影响的研究进展[J].药学实践杂志,2015,33(6):508-512.
[2] 陈晖,蔡泓敏,冯瑞浩,等. CYP2C19和CYP2C19基因多态性对药物代谢的影响及个体化用药研究进展[J].中国药物应用与监测,2014,11(4):240-244.
[3] 蒋兴然,张云岗,路军,等.北方地区汉族消化系统疾病中CYP2C19基因多态性分析[J].临床与实验病理学杂志,2016,32(10):1101-1104.
[4] PROBST SCHENDZIELORZ K,VIVIANI R,STINGL J C.Effect cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors[J].Expert Opin Drug Metab Toxicol,2015,11(8):1219-1224.
[5] 余龙辉,周洁,叶舒慧,等.江西地区心脑血管患者CYP2C19基因多态性检测[J].安徽医科大学学报,2019,54(3):462-465.
[6] MARTIS S,PETER I,HULOT J S,et al.Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes[J].Pharmacogenomics J,2013,13(4):369-374.
[7] DE KESEL P M,LAMBERT W E,STOVE C P.Alternative sampling strategies for cytochrome P450 phenotyping[J].Clin Pharamacokinet,2016,55(2):169-184.
[8] 任凌雁,袁军,陈琨,等.消化道溃疡患者奥美拉唑代谢相关基因CYP2C19的多态性分布[J].贵阳医学院学报,2015,40(10):1051-1053.
[9] 张爱玲,胡欣,杨莉萍.亚洲健康人群CYP2C19基因型发生率的合并分析[J].中国循证医学杂志,2014,14(4):427-434.
[10] 李洁,程莜雯,汪波,等.安徽汉族冠心病患者CYP2C19基因多态性研究[J].安徽医科大学学报,2018,53(5):784-788.
[11] SYCHEV D A,DENISENKO N P,SIZOVA Z M,et al.The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors[J].Pharmgenomics Pers Med,2015,79(8):111-114.
[12] GENOMES PROJECT C,ABECASIS G R,AUTON A,et al.An integrated map of genetic variation from 1092 human genomes[J].Nature,2012,491(7422):56-65.
[13] CASTRO DE GUERRA D,FLORES S,IZAGUIRRE M H.Distribution of CYP2C19*2 and CYP2C19*3 polymorphisms in Venezuelan populations with different admixture[J].Ann Hum Biol,2013,40(2):197-200.
[14] 袁芳,李岚,张玲玲.CYP2C19基因多态性对不同PPI治疗Hp阳性消化性溃疡患者临床效果的影响[J].贵州医药,2018,42(7):798-800.
[15] 盛碧,陈永刚,王慧娟,等.武汉地区314例消化系统疾病患者CYP2C19基因多态性分析[J].中国现代医学杂志,2019,29(2):92-96.
[16] 郑松柏,姚健风. 老年人质子泵抑制剂合理应用专家共识[J].中华老年医学杂志,2015,16(2):1045-1052.
[17] ICHIKAWA H,SUGIMOTO M,SUGIMOTO K,et al.Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis[J].J Gastroenterol Hepatol,2015,31(4):716-726.
[18] JAINAN W,VILAICHONE R K.Effects of the CYP2C19 genetic polymorphism on gastritis,peptic ulcer disease,peptic uncler bleeding and gastric cancer[J].Asian Pac J Cancer Prev,2014,15(24):10957-10960.
[19] DENISENKO N P,SYCHEV D A,ZHM S,et al.High frequency of CYP2C19 ultrarapid metabolizers in russian patients with peptic ulcer[J].Eksp Klin Gastroenterol,2015,3(6):11-15.
[20] SAITO Y,SERIZAWA H,KATO Y,et al.First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype[J].World J Gastroenterol,2015,21(48):13548-13554. |
|
|
|
